dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Bosch-Barrera, J |
dc.contributor.author | Cedres Perez, Susana |
dc.contributor.author | Coves, J. |
dc.contributor.author | Garcia‑Campelo, Rosario |
dc.contributor.author | Guirado Risueño, María |
dc.contributor.author | Nadal, Ernest |
dc.date.accessioned | 2021-07-13T12:07:27Z |
dc.date.available | 2021-07-13T12:07:27Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, et al. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol. 2021 May;23(5):980-987. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/6155 |
dc.description | Clinical guidelines; Malignant pleural mesothelioma; Treatment |
dc.description.abstract | Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;23(5) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Immunoteràpia |
dc.subject | Càncer - Quimioteràpia |
dc.subject | Mesotelioma |
dc.subject.mesh | Mesothelioma |
dc.subject.mesh | Combined Modality Therapy |
dc.title | SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-020-02532-2 |
dc.subject.decs | mesotelioma |
dc.subject.decs | tratamiento combinado |
dc.relation.publishversion | https://link.springer.com/article/10.1007%2Fs12094-020-02532-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Nadal E] Department of Medical Oncology, Catalan Institute of Oncology, Hospital Duran i Reynals, Avda Gran Via 199-203, l’Hospitalet de Llobregat, Barcelona, Spain. [Bosch-Barrera J] Department of Medical Oncology, Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain. [Cedrés S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Coves J] Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain. [García-Campelo R] Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain. [Guirado M] Department of Medical Oncology, Hospital General Universitario de Elche, Elche, Spain |
dc.identifier.pmid | 33538989 |
dc.identifier.wos | 000614690500001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI14%2F01109 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F00920 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |